

Epidemiology, diagnosis and management of hirsutism:
Androgen Excess and Polycystic Ovary Syndrome Society

Human Reproduction Update

18, 146-170

DOI: [10.1093/humupd/dmr042](https://doi.org/10.1093/humupd/dmr042)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Family planning 2011: better use of existing methods, new strategies and more informed choices for female contraception. <i>Human Reproduction Update</i> , 2012, 18, 670-681.	5.2	12
2	Health and fertility in World Health Organization group 2 anovulatory women. <i>Human Reproduction Update</i> , 2012, 18, 586-599.	5.2	105
4	Management of Postmenopausal Virilization. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2584-2588.	1.8	66
5	Concepts of Contraception for Adolescent and Young Adult Women with Chronic Illness and Disability. <i>Disease-a-Month</i> , 2012, 58, 258-320.	0.4	23
6	Hiperandrogenismo y síndrome de ovario poliquístico. <i>Medicine</i> , 2012, 11, 895-903.	0.0	0
7	Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. <i>Endocrine</i> , 2012, 42, 526-534.	1.1	26
8	General Characteristics of Hair in Eating Disorders. , 2013, , 71-77.		0
9	Diagnosis of adolescent polycystic ovary syndrome. <i>Steroids</i> , 2013, 78, 751-754.	0.8	45
10	Polycystic Ovary Syndrome Across Racial and Ethnic Groups. , 2013, , 185-199.		0
11	Testosterone: From Basic Research to Clinical Applications. <i>SpringerBriefs in Reproductive Biology</i> , 2013, , .	0.0	8
13	Phenotypic comparison of Caucasian and Asian women with polycystic ovary syndrome: a cross-sectional study. <i>Fertility and Sterility</i> , 2013, 100, 214-218.	0.5	32
14	Divergences in Insulin Resistance Between the Different Phenotypes of the Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E628-E637.	1.8	186
16	A Diagnosis Not to Be Missed: Nonclassic Steroid 11 β -Hydroxylase Deficiency Presenting With Premature Adrenarche and Hirsutism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1620-E1625.	1.8	63
18	Retinol-binding protein 4, leptin, and insulin resistance in idiopathic hirsutism and hirsute women with polycystic ovary syndrome. <i>Journal of the Egyptian Women's Dermatologic Society</i> , 2013, 10, 94-100.	0.2	1
19	The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2013, 168, 871-877.	1.9	17
20	Routine screening for Cushing's syndrome is not required in patients presenting with hirsutism. <i>European Journal of Endocrinology</i> , 2013, 168, 379-384.	1.9	9
21	UPDATE ON IDIOPATHIC HIRSUTISM: DIAGNOSIS AND TREATMENT. <i>Acta Clinica Belgica</i> , 2013, 68, 268-274.	0.5	9
22	Ethnic-specific polycystic ovary syndrome: epidemiology, significance and implications. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 71-79.	1.2	33

#	ARTICLE	IF	CITATIONS
23	Polycystic Ovary Syndrome in Adolescents. Southern Medical Journal, 2013, 106, 570-576.	0.3	6
26	Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth. International Journal of Reproductive Medicine, 2014, 2014, 1-17.	0.4	247
28	Hirsutism: diagnosis and treatment. Arquivos Brasileiros De Endocrinologia E Metabologia, 2014, 58, 97-107.	1.3	27
29	Puberty and its disorders in the female. , 2014, , 569-663.e1.		22
30	THERAPY OF ENDOCRINE DISEASE: Treatment of hirsutism in the polycystic ovary syndrome. European Journal of Endocrinology, 2014, 170, R75-R90.	1.9	30
31	Hemostatic and Fibrinolytic Abnormalities in Polycystic Ovary Syndrome. Seminars in Thrombosis and Hemostasis, 2014, 40, 600-618.	1.5	18
32	Flutamide: Hirsutism in Women. Hospital Pharmacy, 2014, 49, 517-520.	0.4	7
33	Children's Hospital Association Consensus Statements for Comorbidities of Childhood Obesity. Childhood Obesity, 2014, 10, 304-317.	0.8	74
34	Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review. BMC Women's Health, 2014, 14, 93.	0.8	49
35	Identify underlying cause of hirsutism and individualize treatment as required. Drugs and Therapy Perspectives, 2014, 30, 417-421.	0.3	2
36	Androgens in pregnancy: roles in parturition. Human Reproduction Update, 2014, 20, 542-559.	5.2	162
37	Treatment of Polycystic Ovary Syndrome in Adolescence. Seminars in Reproductive Medicine, 2014, 32, 214-221.	0.5	7
38	Managing the PCOS-Related Symptoms of Hirsutism, Acne, and Hair Loss. , 2014, , 223-242.		1
40	The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. European Journal of Endocrinology, 2014, 171, P1-P29.	1.9	502
41	Increased Expression of Kindlin 2 in Luteinized Granulosa Cells Correlates With Androgen Receptor Level in Patients With Polycystic Ovary Syndrome Having Hyperandrogenemia. Reproductive Sciences, 2014, 21, 696-703.	1.1	13
42	Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer. Steroids, 2014, 90, 94-100.	0.8	27
44	European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire. European Journal of Endocrinology, 2014, 171, 489-498.	1.9	76
45	Hirsutism: An Evidence-Based Treatment Update. American Journal of Clinical Dermatology, 2014, 15, 247-266.	3.3	54

#	ARTICLE	IF	CITATIONS
47	Hyperandrogenemia is implicated in both the metabolic and reproductive morbidities of polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2014, 101, 840-845.	0.5	35
49	Hirsutism: managing the basics. , 0, , 1-10.		0
50	Androgen-producing ovarian tumors. , 0, , 136-145.		0
51	Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment. <i>International Journal of Clinical Practice</i> , 2015, 69, 1236-1246.	0.8	23
52	Interventions for hirsutism (excluding laser and photoepilation therapy alone). <i>The Cochrane Library</i> , 2017, 2017, CD010334.	1.5	26
53	PCOS and Metabolic Syndrome: The Worrisome Twosome?. <i>Endocrinology & Metabolic Syndrome: Current Research</i> , 2015, 04, .	0.3	2
54	Epidemiology and Diagnostic Criteria of Polycystic Ovary Syndrome. <i>Journal of Korean Diabetes</i> , 2015, 16, 189.	0.1	1
55	Pathway Analysis Based on a Genome-Wide Association Study of Polycystic Ovary Syndrome. <i>PLoS ONE</i> , 2015, 10, e0136609.	1.1	33
56	Complementary Therapies for Idiopathic Hirsutism: Topical Licorice as Promising Option. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-6.	0.5	4
57	Hyperandrogenism-Insulin Resistance-Acanthosis Nigricans Syndrome. <i>Case Reports in Endocrinology</i> , 2015, 2015, 1-4.	0.2	8
58	Predictors of Subclinical Cardiovascular Disease in Women with Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and Arterial Blood Pressure. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-9.	0.6	23
59	Total testosterone levels are often more than three times elevated in patients with androgen-secreting tumours. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014204797-bcr2014204797.	0.2	10
60	Genome-wide association study identified new susceptibility loci for polycystic ovary syndrome. <i>Human Reproduction</i> , 2015, 30, 723-731.	0.4	83
61	Polycystic ovary syndrome: chemical pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1369-1393.	0.9	31
62	Total Body Fat and Central Fat Mass Independently Predict Insulin Resistance but Not Hyperandrogenemia In Women With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 661-669.	1.8	54
63	Hormonal Treatment for Skin Androgen-Related Disorders. , 2015, , 1451-1464.		0
64	The Diagnosis of Polycystic Ovary Syndrome during Adolescence. <i>Hormone Research in Paediatrics</i> , 2015, 83, 376-389.	0.8	2,130
65	Is idiopathic hirsutism (IH) really idiopathic? mRNA expressions of skin steroidogenic enzymes in women with IH. <i>European Journal of Endocrinology</i> , 2015, 173, 447-454.	1.9	9

#	ARTICLE	IF	CITATIONS
67	Women self-perception of excess hair growth, as a predictor of clinical hirsutism: a population-based study. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 923-928.	1.8	3
68	Diagnosis and Management of Polycystic Ovary Syndrome (PCOS). , 2015, , 99-113.		9
70	Metabolic Aspects of PCOS. , 2015, , .		6
71	A Comprehensive Approach in Diagnosing the Polycystic Ovary Syndrome. <i>Women's Health</i> , 2015, 11, 501-512.	0.7	8
72	How to manage the reproductive issues of PCOS: a 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 1025-1037.	1.8	18
73	Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. <i>Endocrine Reviews</i> , 2015, 36, 487-525.	8.9	649
74	Interventions for Hirsutism. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1863.	3.8	4
75	Referral bias in female functional hyperandrogenism and polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2015, 173, 603-610.	1.9	26
76	Effects of androgen on immunohistochemical localization of androgen receptor and Connexin 43 in mouse ovary. <i>Tissue and Cell</i> , 2015, 47, 526-532.	1.0	19
77	Testosterone, free testosterone, and free androgen index in women: Reference intervals, biological variation, and diagnostic value in polycystic ovary syndrome. <i>Clinica Chimica Acta</i> , 2015, 450, 227-232.	0.5	45
78	The Diagnosis of Polycystic Ovary Syndrome in Adolescents. <i>Pediatrics</i> , 2015, 136, 1154-1165.	1.0	151
79	Hiperandrogenismo secundario a tumor suprarrenal: causa rara a tener en cuenta. <i>Revista Internacional De Andrología</i> , 2015, 13, 142-145.	0.1	0
80	Inverse relationship between hSHBG affinity for testosterone and hSHBG concentration revealed by surface plasmon resonance. <i>Molecular and Cellular Endocrinology</i> , 2015, 399, 201-207.	1.6	12
81	Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients. <i>Endocrine</i> , 2015, 48, 696-704.	1.1	24
82	Postmenopausal Hyperandrogenism in a Patient With an Adrenal Adenoma: How Should We Approach It?. <i>AACE Clinical Case Reports</i> , 2016, 2, e138-e142.	0.4	1
83	The Relationship between Adiposity and Insulin Sensitivity in African Women Living with the Polycystic Ovarian Syndrome: A Clamp Study. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-6.	0.6	12
84	Current aspects of polycystic ovary syndrome: A literature review. <i>Revista Da Associação Médica Brasileira</i> , 2016, 62, 867-871.	0.3	16
85	Genetic screening of non-classic CAH females with hyperandrogenemia identifies a novel CYP11B1 gene mutation. <i>Hormones</i> , 2016, 15, 235-242.	0.9	0

#	ARTICLE	IF	CITATIONS
86	Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including<sc>GRADE</sc>assessments. British Journal of Dermatology, 2016, 175, 45-61.	1.4	30
87	Prescribing patterns of combined hormonal products containing cyproterone acetate, levonorgestrel and drospirenone in the UK. Journal of Family Planning and Reproductive Health Care, 2016, 42, 247-254.	0.9	4
88	Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis. Diabetes Care, 2016, 39, 639-648.	4.3	71
89	Androgen excess: Investigations and management. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 37, 98-118.	1.4	94
90	Ethnic differences: Is there an Asian phenotype for polycystic ovarian syndrome?. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 37, 46-55.	1.4	47
92	Effectiveness of electroacupuncture for polycystic ovary syndrome: study protocol for a randomized controlled trial. Trials, 2016, 17, 256.	0.7	8
93	The evaluation of endothelial function and structure in hirsute patients in reproductive age. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 206, 208-212.	0.5	4
94	Hirsutism management needs to be more patient oriented. British Journal of Dermatology, 2016, 175, 12-12.	1.4	0
95	What does a diagnostic label of "polycystic ovary syndrome" really mean in adolescence? a review of current practice recommendations. Clinical Obesity, 2016, 6, 1-18.	1.1	14
96	Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome. European Journal of Endocrinology, 2016, 175, 551-560.	1.9	13
97	Protocolo diagnóstico del hiperandrogenismo adrenal. Medicine, 2016, 12, 816-819.	0.0	0
98	Polycystic ovary syndrome. Nature Reviews Disease Primers, 2016, 2, 16057.	18.1	1,004
100	Polycystic ovary syndrome and metabolic syndrome: the worrisome twosome?. Climacteric, 2016, 19, 7-16.	1.1	12
101	Sonographic markers of ovarian morphology, but not hirsutism indices, predict serum total testosterone in women with regular menstrual cycles. Fertility and Sterility, 2016, 105, 1322-1329.e1.	0.5	8
102	Implications of Androgen Assay Accuracy in the Phenotyping of Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 610-618.	1.8	51
103	Clinician vs Self-ratings of Hirsutism in Patients With Polycystic Ovarian Syndrome. JAMA Dermatology, 2016, 152, 783.	2.0	52
104	A genetic risk score is associated with polycystic ovary syndrome-related traits. Human Reproduction, 2016, 31, 209-215.	0.4	16
105	Hyperandrogenism, Hirsutism, and Polycystic Ovary Syndrome. , 2016, , 2275-2296.e6.		2

#	ARTICLE	IF	CITATIONS
106	Caring for women with polycystic ovary syndrome. <i>Nurse Practitioner</i> , 2017, 42, 39-47.	0.2	1
107	Hyperandrogenism in a postmenopausal woman: a rare case of ectopic adrenal cortical gland. <i>Gynecological Endocrinology</i> , 2017, 33, 185-187.	0.7	4
109	Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects. <i>European Journal of Contraception and Reproductive Health Care</i> , 2017, 22, 183-190.	0.6	24
110	Association between biochemical hyperandrogenism parameters and Ferriman-Gallwey score in patients with polycystic ovary syndrome: A systematic review and meta-regression analysis. <i>Clinical Endocrinology</i> , 2017, 87, 217-230.	1.2	40
111	Polycystic ovary morphology is associated with insulin resistance in women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2017, 87, 375-380.	1.2	12
112	Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. <i>Human Reproduction Update</i> , 2017, 23, 580-599.	5.2	136
113	Maternal hirsutism and autism spectrum disorders in offspring. <i>Autism Research</i> , 2017, 10, 1544-1546.	2.1	14
114	Association of ethnicity, Fitzpatrick skin type, and hirsutism: A retrospective cross-sectional study of women with polycystic ovarian syndrome. <i>International Journal of Women's Dermatology</i> , 2017, 3, 37-43.	1.1	46
116	No. 350-Hirsutism: Evaluation and Treatment. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, 1054-1068.	0.3	5
117	Pharmacologic Treatment of Polycystic Ovary Syndrome: Alternate and Future Paths. <i>Seminars in Reproductive Medicine</i> , 2017, 35, 326-343.	0.5	4
118	Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. <i>European Journal of Endocrinology</i> , 2017, 177, 399-408.	1.9	23
119	An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. <i>Hormone Research in Paediatrics</i> , 2017, 88, 371-395.	0.8	282
121	Polycystic Ovarian Syndrome: Long-Term Health Consequences. <i>Seminars in Reproductive Medicine</i> , 2017, 35, 271-281.	0.5	38
122	Lipid Accumulation Product (LAP) and Visceral Adiposity Index (VAI) as Markers of Insulin Resistance and Metabolic Associated Disturbances in Young Argentine Women with Polycystic Ovary Syndrome. <i>Hormone and Metabolic Research</i> , 2017, 49, 23-29.	0.7	40
123	No 350-Hirsutisme : Évaluation et traitement. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, 1069-1084.	0.3	1
124	Acne-Associated Syndromes. , 0, , .		1
125	Polycystic ovary syndrome in adolescence: diagnostic and therapeutic strategies. <i>Translational Pediatrics</i> , 2017, 6, 248-255.	0.5	41
126	Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits. <i>Open Access Journal of Contraception</i> , 2017, Volume 8, 13-23.	0.6	32

#	ARTICLE	IF	CITATIONS
127	Evaluation and Treatment of Hirsutism in Premenopausal Women. JAMA - Journal of the American Medical Association, 2018, 319, 1613.	3.8	20
128	Causes, Patterns, and Severity of Androgen Excess in 1205 Consecutively Recruited Women. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1214-1223.	1.8	50
129	Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1258-1264.	1.8	50
130	Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society* Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1233-1257.	1.8	205
131	MANAGEMENT OF ENDOCRINE DISEASE Hyperandrogenic states in women: pitfalls in laboratory diagnosis. European Journal of Endocrinology, 2018, 178, R141-R154.	1.9	19
132	New perspectives on the definition and management of polycystic ovary syndrome. Journal of Endocrinological Investigation, 2018, 41, 1123-1135.	1.8	42
133	What is adolescent polycystic ovary syndrome?. Journal of Paediatrics and Child Health, 2018, 54, 351-355.	0.4	16
134	Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update, 2018, 24, 225-241.	5.2	36
135	Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology, 2018, 14, 270-284.	4.3	1,013
136	Delayed presentation of a virilising, pure testosterone-secreting adrenocortical carcinoma with coexistent composite myelolipoma and a venous thrombus extending to the heart. BMJ Case Reports, 2018, 2018, bcr-2017-223117.	0.2	0
137	DNA methylation of the androgen receptor gene promoter in the granulosa cells of polycystic ovary syndrome patients. Journal of Physics: Conference Series, 2018, 1073, 032078.	0.3	1
138	Prenatal Androgenization of Ewes as a Model of Hirsutism in Polycystic Ovary Syndrome. Endocrinology, 2018, 159, 4056-4064.	1.4	5
139	Non-classical 11 β -hydroxylase deficiency caused by compound heterozygous mutations: a case study and literature review. Journal of Ovarian Research, 2018, 11, 82.	1.3	14
140	Disorders of the Scalp and Hair. , 2018, , 385-397.		0
141	A Summary on Polycystic Ovary Syndrome: Diagnostic Criteria, Prevalence, Clinical Manifestations, and Management According to the Latest International Guidelines. Seminars in Reproductive Medicine, 2018, 36, 005-012.	0.5	115
142	Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews. Clinical Endocrinology, 2018, 89, 535-553.	1.2	16
143	A Cohort Study Comparing Women with Autism Spectrum Disorder with and without Generalized Joint Hypermobility. Behavioral Sciences (Basel, Switzerland), 2018, 8, 35.	1.0	12
144	Acromegaly Presenting as Severe Hirsutism and Amenorrhoea. AACE Clinical Case Reports, 2018, 4, 153-156.	0.4	0

#	ARTICLE	IF	CITATIONS
145	Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome. <i>Journal of Women's Health</i> , 2018, 27, 892-902.	1.5	14
146	Evaluation of Hormonal Status. , 2019, , 887-915.e4.		8
147	Management of Adolescent Hyperandrogenism: Still a Challenge?. <i>ISGE Series</i> , 2019, , 83-92.	0.2	0
148	First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. <i>Human Reproduction Update</i> , 2019, 25, 717-732.	5.2	71
149	Difficulties in diagnostics of polycystic ovary syndrome in adolescents â€“ a preliminary study. <i>Pediatric Endocrinology, Diabetes and Metabolism</i> , 2019, 25, 122-126.	0.3	4
151	Polycystic Ovary Syndrome in Adolescents: Challenges in Diagnosis and Treatment. <i>International Journal of Endocrinology and Metabolism</i> , 2019, 17, e91554.	0.3	28
152	Endocrinology of Hirsutism: From Androgens to Androgen Excess Disorders. <i>Frontiers of Hormone Research</i> , 2019, 53, 108-119.	1.0	22
154	Insulin resistance is associated with hirsutism in unselected reproductive-aged women. <i>Clinical Endocrinology</i> , 2019, 90, 586-591.	1.2	5
155	The management of hirsutism. <i>InnovAiT</i> , 2019, 12, 448-453.	0.0	0
156	Quality of life among infertile PCOS patients. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 461-467.	0.8	22
157	Androgens in women. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1509-1521.	0.6	41
158	Androgens in women. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1497-1506.	0.6	67
159	Polycystic ovary syndrome in adult women. <i>Medicina Clínica (English Edition)</i> , 2019, 152, 450-457.	0.1	12
160	Paraneoplastic syndromes and other systemic disorders associated with neuroendocrine neoplasms. <i>Seminars in Diagnostic Pathology</i> , 2019, 36, 229-239.	1.0	13
161	Diagnosis and Management of Congenital Adrenal Hyperplasia in Children and Adults. , 2019, , 657-678.		1
163	Vitamin D receptor and binding protein polymorphisms in women with polycystic ovary syndrome: a case control study. <i>BMC Endocrine Disorders</i> , 2019, 19, 145.	0.9	5
164	Screening and Management of the Hyperandrogenic Adolescent. <i>Obstetrics and Gynecology</i> , 2019, 134, e106-e114.	1.2	19
165	The diagnosis and treatment of PCOS in adolescents: an update. <i>Current Opinion in Pediatrics</i> , 2019, 31, 562-569.	1.0	60

#	ARTICLE	IF	CITATIONS
166	Prevalence and degree of insulin resistance in Chinese Han women with PCOS: Results from euglycemic hyperinsulinemic clamps. <i>Clinical Endocrinology</i> , 2019, 90, 138-144.	1.2	21
167	The relationship between clinical and biochemical characteristics and quality of life in patients with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2019, 90, 129-137.	1.2	19
168	Síndrome de ovario poliquístico en la mujer adulta. <i>Medicina Clínica</i> , 2019, 152, 450-457.	0.3	22
169	Diagnostic pitfalls in ovarian androgen-secreting (Leydig cell) tumours: case series. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 359-364.	0.4	6
170	Relationships Between Biochemical Markers of Hyperandrogenism and Metabolic Parameters in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. <i>Hormone and Metabolic Research</i> , 2019, 51, 22-34.	0.7	12
171	Socioeconomic status in Danish women with polycystic ovary syndrome: A register-based cohort study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019, 98, 440-450.	1.3	10
172	Higher luteinizing hormone levels associated with anti-müllerian hormone in postmenarchal daughters of women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2019, 111, 381-388.	0.5	48
173	Genome-Wide Association Studies of Ovarian Function Disorders. , 2019, , 311-325.		0
174	Evaluation of serum level of omentin-1 in females with hirsutism. <i>Journal of Cosmetic Dermatology</i> , 2020, 19, 535-539.	0.8	4
175	Contraception across the transmasculine spectrum. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 134-143.	0.7	99
177	Managing Women's Hyperandrogenism. , 2020, , .		0
178	Anti-androgen hormonal therapy for cancer and other diseases. <i>European Journal of Pharmacology</i> , 2020, 866, 172783.	1.7	38
179	A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial. <i>Human Reproduction</i> , 2020, 35, 175-186.	0.4	17
180	Several critical genes and microRNAs associated with the development of polycystic ovary syndrome. <i>Annales D'Endocrinologie</i> , 2020, 81, 18-27.	0.6	22
184	Diagnosis and Treatment of Polycystic Ovary Syndrome in Adolescent Females. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 544-552.	0.6	10
185	Endocrine Pathophysiology. , 2020, , .		1
186	The predictive value of total testosterone alone for clinical hyperandrogenism in polycystic ovary syndrome. <i>Reproductive BioMedicine Online</i> , 2020, 41, 734-742.	1.1	9
187	Hormonal Effects on Hair Follicles. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5342.	1.8	94

#	ARTICLE	IF	CITATIONS
188	Sexual function and depression in polycystic ovary syndrome: Is it associated with inflammation and neuromodulators?. <i>Neuropeptides</i> , 2020, 84, 102099.	0.9	7
189	Effects of oral contraceptives on the quality of life of women with polycystic ovary syndrome: a crossover randomized controlled trial. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 293.	1.0	8
190	S�ndrome de ovarios poliqu�sticos. <i>EMC - Ginecolog�a-Obstetricia</i> , 2020, 56, 1-18.	0.0	0
191	Is Idiopathic Hirsutism Truly Idiopathic?. <i>Journal of Obstetrics and Gynecology of India</i> , 2020, 70, 366-370.	0.3	1
192	Evaluation of quality of life of patients with hirsutism among Turkish women: A single�center cross�sectional study. <i>Journal of Cosmetic Dermatology</i> , 2020, 19, 3053-3057.	0.8	6
193	Cutaneous manifestations of polycystic ovary syndrome. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2020, 12, 49-52.	0.6	7
194	Menstrual patterns and self-reported hirsutism as assessed via the modified Ferriman-Gallwey scale: A cross-sectional study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 248, 137-143.	0.5	5
195	The role of androgen receptor CAG repeat polymorphism in androgen excess disorder and idiopathic hirsutism. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1271-1281.	1.8	10
196	Serum Androgens Are Independent Predictors of Insulin Clearance but Not of Insulin Secretion in Women With PCOS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1981-e1989.	1.8	14
197	Relationship between the characteristic traits of polycystic ovary syndrome and susceptibility genes. <i>Scientific Reports</i> , 2020, 10, 10479.	1.6	22
198	First Report of Retroperitoneal Mucinous Cystadenoma in a Patient with Hirsutism. <i>Clinical Medicine and Research</i> , 2020, 18, 27-32.	0.4	2
199	Drug reactions affecting hair and nails. <i>Clinics in Dermatology</i> , 2020, 38, 693-701.	0.8	2
200	Disorders of Pubertal Onset. <i>Primary Care - Clinics in Office Practice</i> , 2020, 47, 189-216.	0.7	9
201	Distribution of Body Hair in Young Australian Women and Associations With Serum Androgen Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1186-1195.	1.8	10
202	Hair, Hormones, and Haunting: Race as a Ghost Variable in Polycystic Ovary Syndrome. <i>Science Technology and Human Values</i> , 2020, 45, 779-803.	1.7	4
203	Is There Any Association Between Hirsutism and Serum Zinc Levels in Adolescents?. <i>Biological Trace Element Research</i> , 2020, 198, 403-409.	1.9	4
205	Clinical Implications of Polycystic Ovary Syndrome in Adolescents. <i>Nursing for Women's Health</i> , 2020, 24, 115-126.	0.3	5
206	Effects of oral contraceptives on serum concentrations of adipokines and adiposity indices of women with polycystic ovary syndrome: a randomized controlled trial. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 567-580.	1.8	2

#	ARTICLE	IF	CITATIONS
207	The effect of PCOS status on atherosclerosis markers and cardiovascular disease risk factors in young women with vitamin D deficiency. <i>Gynecological Endocrinology</i> , 2021, 37, 225-229.	0.7	4
208	Influence of ethnicity on different aspects of polycystic ovary syndrome: a systematic review. <i>Reproductive BioMedicine Online</i> , 2021, 42, 799-818.	1.1	26
209	The Role of Probiotics and Synbiotics on Hirsutism. <i>Fermentation</i> , 2021, 7, 10.	1.4	4
210	Hyperandrogenism, Insulin Resistance, and Acanthosis Nigricans (HAIR-AN) Syndrome Reflects Adipose Tissue Dysfunction (Adiposopathy or Sick Fat) in Asian Indian Girls. <i>Dermatology</i> , 2021, 237, 797-805. ^{0.9}		3
211	Postprandial responses of circulating energy homeostasis mediators to single macronutrient challenges: influence of obesity and sex hormones. <i>Food and Function</i> , 2021, 12, 1051-1062.	2.1	5
212	Is polycystic ovary syndrome appropriately diagnosed by obstetricians and gynaecologists across China: a nationwide survey. <i>Journal of Ovarian Research</i> , 2021, 14, 25.	1.3	8
213	Why are Women With Polycystic Ovary Syndrome at Increased Risk of Depression? Exploring the Etiological Maze. <i>Cureus</i> , 2021, 13, e13489.	0.2	5
214	Ovarian Leydig cell tumor and postmenopausal hirsutism with signs of virilisation. <i>BMJ Case Reports</i> , 2021, 14, e240937.	0.2	5
215	Health related quality of life and psychological parameters in different polycystic ovary syndrome phenotypes: a comparative cross-sectional study. <i>Journal of Ovarian Research</i> , 2021, 14, 57.	1.3	14
216	Effect of body mass index (BMI) on phenotypic features of polycystic ovary syndrome (PCOS) in Singapore women: a prospective cross-sectional study. <i>BMC Women's Health</i> , 2021, 21, 135.	0.8	22
217	Polycystic ovary syndrome: clinical and pathogenetic aspects of a multidisciplinary problem. <i>Reproductive Health of Woman</i> , 0, 2, 7-14.	0.0	1
218	Eflornithine. <i>Journal of the Dermatology Nurses' Association</i> , 2021, 13, 179-182.	0.1	0
219	Insulin-Mediated Substrate Use in Women With Different Phenotypes of PCOS: the Role of Androgens. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3414-e3425.	1.8	12
221	Clinico-investigative attributes of 122 patients with hirsutism: A 5-year retrospective study from India. <i>International Journal of Women's Dermatology</i> , 2021, 7, 237-242.	1.1	5
222	PCOS Features and Steroid Profiles Among Young Adult Women with a History of Premature Adrenarche. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3335-e3345.	1.8	8
223	Bioinformatics Analysis of ceRNA Network Related to Polycystic Ovarian Syndrome. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-20.	0.7	2
224	The Prevalence of Clinical Characteristics of Polycystic Ovary Syndrome among Indigenous Women: A Systematic Search and Review of the Literature. <i>Seminars in Reproductive Medicine</i> , 2021, 39, 078-093.	0.5	0
225	Prevalence of idiopathic hirsutism: A systematic review and meta-analysis. <i>Journal of Cosmetic Dermatology</i> , 2021, , .	0.8	6

#	ARTICLE	IF	CITATIONS
226	Management of Fully Pubertal Girls With Nonclassical Congenital Adrenal Hyperplasia: Glucocorticoids Versus Oral Contraceptives. <i>Endocrine Practice</i> , 2021, , .	1.1	0
227	Inhibiting Kiss1 Neurons With Kappa Opioid Receptor Agonists to Treat Polycystic Ovary Syndrome and Vasomotor Symptoms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e328-e347.	1.8	13
228	Prevalence of Hirsutism Among Reproductiveâ€”Aged African American Women. <i>Journal of Women's Health</i> , 2021, 30, 1580-1587.	1.5	6
229	Practical Approach to Hyperandrogenism in Women. <i>Medical Clinics of North America</i> , 2021, 105, 1099-1116.	1.1	8
230	Non-linear and non-additive associations between the pregnancy metabolome and birthweight. <i>Environment International</i> , 2021, 156, 106750.	4.8	8
231	Androgen excess in women. , 2022, , 810-823.e3.		0
232	Grading of hirsutism: a practical approach to the modified Ferriman-Gallwey scoring system. <i>Postepy Dermatologii i Alergologii</i> , 2022, 39, 744-748.	0.4	4
233	Abnormal Uterine Bleeding in the Adolescent. , 2021, , .		0
234	Disorders of Hair and Nails. , 2016, , 136-174.e9.		2
236	Genetic Alterations within the DENND1A Gene in Patients with Polycystic Ovary Syndrome (PCOS). <i>PLoS ONE</i> , 2013, 8, e77186.	1.1	34
238	The Role of Serum MicroRNA-6767-5p as a Biomarker for the Diagnosis of Polycystic Ovary Syndrome. <i>PLoS ONE</i> , 2016, 11, e0163756.	1.1	24
239	Insulin resistance according to Î²-cell function in women with polycystic ovary syndrome and normal glucose tolerance. <i>PLoS ONE</i> , 2017, 12, e0178120.	1.1	23
240	ACUPCOS: Acupuncture & PCOS â€” A Multi-Centres Randomised Controlled Trial. <i>International Journal of Gynecological and Obstetrical Research</i> , 2014, 2, 1-13.	0.1	8
241	MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of the patient with non-classic CAH due to 21-hydroxylase deficiency. <i>European Journal of Endocrinology</i> , 2019, 180, R127-R145.	1.9	103
242	Current guidelines for the treatment of polycystic ovary syndrome: benefits of oral contraceptives with antiandrogenic progestins. <i>Russian Journal of Human Reproduction</i> , 2017, 23, 56.	0.1	1
243	Assessing Whether Meditation Improves Quality of Life for Adolescent Girls With Polycystic Ovary Syndrome: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e14542.	0.5	5
244	Comparing the Effects of Oral Contraceptives Containing Levonorgestrel With Products Containing Antiandrogenic Progestins on Clinical, Hormonal, and Metabolic Parameters and Quality of Life in Women With Polycystic Ovary Syndrome: Crossover Randomized Controlled Trial Protocol. <i>JMIR Research Protocols</i> , 2017, 6, e191.	0.5	2
245	ASSESSMENT OF SERUM ZINC LEVEL IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME. <i>Iraqi Journal of Medical Sciences</i> , 2017, 15, .	0.0	2

#	ARTICLE	IF	CITATIONS
246	Current treatment for polycystic ovary syndrome: focus on adolescence. <i>Minerva Pediatrica</i> , 2020, 72, 288-311.	2.6	7
247	The Modified Ferriman-Gallwey Score and Hirsutism among Filipino Women. <i>Endocrinology and Metabolism</i> , 2019, 34, 374.	1.3	20
248	Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-MÅ¼llerian hormone cutoff value. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 690-698.	0.7	24
249	Survey of Cutaneous Manifestations in Adolescents Suffering from Poly Cystic Ovarian Syndrome. <i>Asian Journal of Dermatology</i> , 2012, 5, 11-21.	0.0	3
250	Adolescent Polycystic Ovary Syndrome: An Update. <i>Pediatric Annals</i> , 2019, 48, e304-e310.	0.3	10
251	Modified Ferrimanâ€™Gallwey score in hirsutism and its association with metabolic syndrome. <i>International Journal of Trichology</i> , 2017, 9, 7.	0.1	31
252	Polycystic Ovary Syndrome Endocrine and Cardio-Metabolic Abnormalities: how to Manage?. <i>Acta Endocrinologica</i> , 2015, 11, 77-84.	0.1	4
253	Metabolic effects of polycystic ovary syndrome in adolescents. <i>Annals of Pediatric Endocrinology and Metabolism</i> , 2015, 20, 136.	0.8	13
254	Association between biochemical hyperandrogenism parameters and modified Ferriman-Gallwey score in patients with hirsutism in Basrah (Southern Iraq). <i>Postepy Dermatologii I Alergologii</i> , 2021, 38, 603-607.	0.4	2
255	Modern approach to the treatment of patients with androgen-dependent dermatopathies. <i>Meditinskiy Sovet</i> , 2021, , 94-100.	0.1	0
256	The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 583-595.	1.8	14
257	Correlation of Clinical, Hormonal, Biochemical and Ultrasound Parameters Between Adult and Adolescent Polycystic Ovarian Syndrome. <i>Journal of Obstetrics and Gynecology of India</i> , 2022, 72, 274-280.	0.3	3
258	The Comparison of Gender Dysphoria, Body Image Satisfaction and Quality of Life Between Treatment-Naive Transgender Males With and Without Polycystic Ovary Syndrome. <i>Transgender Health</i> , 0, , .	1.2	3
259	Manipulating Androgens for Therapy. <i>SpringerBriefs in Reproductive Biology</i> , 2013, , 59-69.	0.0	0
260	Hirsutism and Virilization. , 2014, , 145-157.		0
263	Severe facial hirsutism following isotretinoin therapy: An under-reported entity. <i>International Journal of Trichology</i> , 2015, 7, 129.	0.1	2
264	National consensus on the management of patients with hyperandrogenism (2016). <i>Reproductive Endocrinology</i> , 2016, .	0.0	6
265	Disorders of Hair and Nail. , 2017, , 91-112.		0

#	ARTICLE	IF	CITATIONS
266	Evaluation and Management of Hirsutism in Postmenopausal Women. , 2017, , 209-219.		1
268	The effect of metformin on clinical features of women with polycystic ovary syndrome. <i>Medicinski Podmladak</i> , 2018, 69, 65-73.	0.2	0
269	Postmenopausal Hyperandrogenism. <i>Journal of Women's Health Care</i> , 2018, 07, .	0.2	0
270	Hirsutisme. , 2019, , 324-328.		0
271	Le syndrome des ovaires polykystiques. , 2019, , 159-177.		0
272	Stratégie d'exploration des hyperandrogénies. , 2019, , 139-148.		0
273	Clinical Features and Assessment of Hyperandrogenism: Differential Diagnosis for Clinical Use. , 2020, , 21-33.		0
274	<i>General Dermatology</i> . , 2020, , 223-256.		0
275	Leydig cell ovarian tumor " clinical case description and literature review. <i>Przegląd Menopauzalny</i> , 2020, 19, 140-143.	0.6	2
276	Postmenopausal Alopecia due to Ovarian Hyperandrogenemia Treated with Bilateral Salpingo-oophorectomy. <i>Journal of SAFOG</i> , 2020, 12, 182-183.	0.1	0
277	Testosterone or Dehydroepiandrosterone Sulfate as a Biomarker for Hirsutism in Women with Polycystic Ovary Syndrome. <i>Biomedical and Pharmacology Journal</i> , 2020, 13, 1815-1823.	0.2	1
278	<i>Reproductive Organ Signs</i> . , 2020, , 127-149.		0
279	Investigation of body mass index, insulin resistance and diabetes in patients with hirsutism. <i>Postepy Dermatologii i Alergologii</i> , 2021, 38, 1006-1010.	0.4	3
281	Polycystic ovary syndrome: individualized approach to treatment. Literature review. <i>Reproductive Endocrinology</i> , 2020, .	0.0	1
282	Is There Any Association Between Clinical and Biochemical Hyperandrogenism in Women With Female Pattern Hair Loss?. <i>Cureus</i> , 2020, 12, e11732.	0.2	2
283	Approach to the management of idiopathic hirsutism. <i>Canadian Family Physician</i> , 2012, 58, 173-7.	0.1	1
284	Metformin-clinical pharmacology in PCOs. <i>Journal of Medicine and Life</i> , 2015, 8, 187-92.	0.4	31
285	The multifarious role of insulin in PCOS: From pathophysiology to therapeutic management. , 2022, , 39-54.		0

#	ARTICLE	IF	CITATIONS
286	Defining PCOS: A syndrome with an intrinsic heterogeneous nature. , 2022, , 3-13.		4
287	Combined oral contraceptives: Why, when, where?. , 2022, , 135-152.		1
288	Bloodletting has no effect on the blood pressure abnormalities of hyperandrogenic women taking oral contraceptives in a randomized clinical trial. Scientific Reports, 2021, 11, 22097.	1.6	0
290	The Effect of Myoinositol and Metformin on Cardiovascular Risk Factors in Women with Polycystic Ovary Syndrome: a Randomized Controlled Trial. Acta Endocrinologica, 2021, 17, 241-247.	0.1	3
291	Polycystic ovary syndrome phenotype does not have impact on oocyte morphology. Reproductive Biology and Endocrinology, 2022, 20, 7.	1.4	7
292	Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients. Reproductive Biology and Endocrinology, 2022, 20, 6.	1.4	11
293	MiR-520h inhibits viability and facilitates apoptosis of KGN cells through modulating IL6R and the JAK/STAT pathway. Reproductive Biology, 2022, 22, 100607.	0.9	6
294	Testosterone level correlates significantly with luteinizing hormone to follicle-stimulating hormone ratio among women with polycystic ovary syndrome: A cross sectional study. F1000Research, 0, 11, 152.	0.8	0
296	Hypertension Predisposition and Thermoregulation Delays in Adolescents with Polycystic Ovary Syndrome: A Pilot Study. Children, 2022, 9, 316.	0.6	1
298	Which laboratory/ultrasonographic parameters affect the severity of hirsutism?. Journal of Cosmetic Dermatology, 2022, 21, 4927-4930.	0.8	2
299	The association between triglycerides/high-density lipoprotein cholesterol ratio, insulin resistance, and serum androgen levels in patients with polycystic ovary syndrome. The European Research Journal, 2022, 8, 275-281.	0.1	1
300	Investigation of the mechanisms and experimental verification of Cuscuta-Salvia in the treatment of polycystic ovary syndrome (PCOS) via network pharmacology. Journal of Ovarian Research, 2022, 15, 40.	1.3	5
301	Clinical Value of Serum Levels of 11-Oxygenated Metabolites of Testosterone in Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2047-e2055.	1.8	9
302	Effect of Electroacupuncture on Reproductive Disorders and Insulin Resistance in a Murine Polycystic Ovary Syndrome Model. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-12.	0.5	2
303	The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology, 2021, 19, 189.	1.4	8
305	For what reasons should metformin be used in the management of polycystic ovary syndrome?. Journal of Endocrinological Investigation, 2012, 35, 87-9.	1.8	2
306	Possible efficacy of Lavender and Tea tree oils in the treatment of young women affected by mild idiopathic hirsutism. Journal of Endocrinological Investigation, 2013, 36, 50-4.	1.8	1
308	Physical Examination for Endocrine Diseases: Does It Still Play a Role?. Journal of Clinical Medicine, 2022, 11, 2598.	1.0	2

#	ARTICLE	IF	CITATIONS
309	Long-Lasting Effects of Spironolactone after its Withdrawal in Patients with Hyperandrogenic Skin Disorders. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2023, 23, 188-195.	0.6	2
310	A Multiclassifier System to Identify and Subtype Congenital Adrenal Hyperplasia Based on Circulating Steroid Hormones. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3304-e3312.	1.8	4
311	Testosterone level correlates significantly with luteinizing hormone to follicle-stimulating hormone ratio among women with polycystic ovary syndrome: A cross sectional study. <i>F1000Research</i> , 0, 11, 152.	0.8	0
312	Challenges in diagnosis and understanding of natural history of polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2022, 97, 165-173.	1.2	13
315	Practical approaches to the use of markers of biochemical hyperandrogenism in women. <i>Reproductive Endocrinology</i> , 2022, , 25-33.	0.0	0
316	Effect of Iron Depletion by Bloodletting vs. Observation on Oxidative Stress Biomarkers of Women with Functional Hyperandrogenism Taking a Combined Oral Contraceptive: A Randomized Clinical Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 3864.	1.0	2
317	The Efficacy of Chinese Herbal Medicine in Animal Models of Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-14.	0.5	2
318	Hirsutism, Normal Androgens and Diagnosis of PCOS. <i>Diagnostics</i> , 2022, 12, 1922.	1.3	11
319	An update on polycystic ovary syndrome: A review of the current state of knowledge in diagnosis, genetic etiology, and emerging treatment options. <i>Women's Health</i> , 2022, 18, 174550572211179.	0.7	8
320	Prevalence of polycystic ovary syndrome in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
321	Clinical Concerns on Sex Steroids Variability in Cisgender and Transgender Women Athletes. <i>International Journal of Sports Medicine</i> , 2023, 44, 81-94.	0.8	1
322	Representation of Asian American Populations in Medical School Curricula. <i>JAMA Network Open</i> , 2022, 5, e2233080.	2.8	4
323	Sexuality and psychological well-being in different polycystic ovary syndrome phenotypes compared with healthy controls: a cross-sectional study. <i>BMC Women's Health</i> , 2022, 22, .	0.8	4
324	A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS). <i>Journal of Assisted Reproduction and Genetics</i> , 2022, 39, 2439-2473.	1.2	32
325	Hyperandrogenism caused by a rare adrenocortical oncocytic neoplasm with uncertain malignant potential: a case report and review of the literature. <i>Endocrine Journal</i> , 2022, , .	0.7	1
326	Assessment of Insulin Therapy as a Risk Factor for Hirsutism Among Diabetic Females in Saudi Arabia. <i>Cureus</i> , 2022, , .	0.2	0
327	Ethnicity in polycystic ovary syndrome. <i>Climacteric</i> , 0, , 1-6.	1.1	0
328	Effects of Hormones and Endocrine Disorders on Hair Growth. <i>Cureus</i> , 2022, , .	0.2	1

#	ARTICLE	IF	CITATIONS
329	Comparison of image-based modified Ferriman-Gallway score evaluation with in-person evaluation: an alternative method for hirsutism diagnosis. Archives of Dermatological Research, 2023, 315, 1783-1787.	1.1	1
330	Hyperandrogenic Symptoms Are a Persistent Suffering in Midlife Women with PCOS; a Prospective Cohort Study in Sweden. Biomedicines, 2023, 11, 96.	1.4	2
332	Fifteen-minute consultation: Approach to the adolescent presenting with hirsutism. Archives of Disease in Childhood: Education and Practice Edition, 0, , edpract-2022-324465.	0.3	0
333	Validation of circulating microRNAs miR-142-3p and miR-598-3p in women with polycystic ovary syndrome as potential diagnostic markers. Human Reproduction, 2023, 38, 951-960.	0.4	1
334	Current Guidelines for Diagnosing PCOS. Diagnostics, 2023, 13, 1113.	1.3	23
335	Polycystic Ovarian Syndrome. ISGE Series, 2023, , 95-121.	0.2	0
336	Molecular Mechanisms in the Etiology of Polycystic Ovary Syndrome (PCOS): A Multifaceted Hypothesis Towards the Disease with Potential Therapeutics. Indian Journal of Clinical Biochemistry, 2024, 39, 18-36.	0.9	2
337	An evaluation of the available pharmacotherapy for the treatment of hirsutism. Expert Opinion on Pharmacotherapy, 2023, 24, 803-813.	0.9	0
338	Polycystic ovary syndrome in adolescents. , 2024, , 11-22.		0
339	Maternal androgen excess increases the risk of pre-diabetes mellitus in male offspring in later life: a long-term population-based follow-up study. Journal of Endocrinological Investigation, 2023, 46, 1775-1785.	1.8	1
355	Skin Androgen-Related Disorders: Hormonal Treatment. , 2023, , 1661-1678.		0
359	Hirsutisme. , 2024, , 356-360.		0